Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Survey reveals knowledge gap

This article was originally published in The Tan Sheet

Executive Summary

A survey released Dec. 13 by the National Women's Health Resource Center determines although 51 percent of the people surveyed take a multivitamin, most do not know which vitamins and minerals are essential for their bodies or which are responsible for specific functions in the body. Based on 1,009 online interviews research firm Ipsos conducted with adults from 25 to 65 years old across the U.S., "we are concerned by their lack of knowledge - especially among women, who are more likely to take an active role in maintaining their family's health," says Elizabeth Battaglino Cahill, a nurse and executive VP of NWHRC. Survey results show 49 percent of Americans are very or somewhat concerned about low density lipoprotein cholesterol, but only 24 percent understand taking a vitamin with phytosterols can help lower LDL. Also, when asked to choose from a list of vitamins which one can help maintain healthy eyesight, only 27 percent of participants correctly identified vitamin A...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts